List view / Grid view


Sanofi reports positive Phase 3 results for Toujeo®

19 June 2014 | By Sanofi

Sanofi announced that, in a pooled analysis, investigational therapy Toujeo® (insulin glargine [rDNA origin] injection, 300 U/mL) consistently showed significantly fewer low blood sugar events (hypoglycemia)...

MSD to acquire Idenix

9 June 2014 | By Merck

MSD and Idenix Pharmaceuticals, Inc. announced that the companies have entered into a definitive agreement under which MSD will acquire Idenix for $24.50 per share in cash...